Source:http://linkedlifedata.com/resource/pubmed/id/19303104
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions |
umls-concept:C0005682,
umls-concept:C0010583,
umls-concept:C0010692,
umls-concept:C0021368,
umls-concept:C0021469,
umls-concept:C0022947,
umls-concept:C0026336,
umls-concept:C0031715,
umls-concept:C0034693,
umls-concept:C0034721,
umls-concept:C0036847,
umls-concept:C0070126,
umls-concept:C0205263,
umls-concept:C0521447,
umls-concept:C1536696
|
| pubmed:issue |
5
|
| pubmed:dateCreated |
2009-4-13
|
| pubmed:abstractText |
Cyclophosphamide (Sigma) is associated with urological complications, including irritative voiding symptoms and hemorrhagic cystitis. Evidence suggests that tumor necrosis factor-alpha (R&D Systems), interleukin-1beta and cyclooxygenase-2 are directly involved in the pathogenesis of cyclophosphamide induced cystitis and these molecules depend on transcription factor NF-kappaB for maximal secretion. Additionally, sesquiterpene lactone parthenolide has been shown to be a potent nuclear factor-kappaB inhibitor. We hypothesized that enhanced nuclear factor-kappaB activity contributes to cyclophosphamide induced cystitis and, therefore, it may be an attractive target for preventing cyclophosphamide cystitis. We determined whether parthenolide could be used as a preventive agent for hemorrhagic cystitis and bladder overactivity. Moreover, we determined the molecular mechanisms of parthenolide on the inhibitory action of nuclear factor-kappaB in inflammatory human benign urothelial cells.
|
| pubmed:commentsCorrections | |
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
AIM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
May
|
| pubmed:issn |
1527-3792
|
| pubmed:author | |
| pubmed:issnType |
Electronic
|
| pubmed:volume |
181
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
2339-48
|
| pubmed:meshHeading |
pubmed-meshheading:19303104-Analysis of Variance,
pubmed-meshheading:19303104-Animals,
pubmed-meshheading:19303104-Biopsy, Needle,
pubmed-meshheading:19303104-Cyclophosphamide,
pubmed-meshheading:19303104-Cystitis,
pubmed-meshheading:19303104-Disease Models, Animal,
pubmed-meshheading:19303104-Female,
pubmed-meshheading:19303104-Immunohistochemistry,
pubmed-meshheading:19303104-Male,
pubmed-meshheading:19303104-NF-kappa B,
pubmed-meshheading:19303104-Phosphorylation,
pubmed-meshheading:19303104-Probability,
pubmed-meshheading:19303104-Random Allocation,
pubmed-meshheading:19303104-Rats,
pubmed-meshheading:19303104-Rats, Sprague-Dawley,
pubmed-meshheading:19303104-Sensitivity and Specificity,
pubmed-meshheading:19303104-Sesquiterpenes,
pubmed-meshheading:19303104-Urinary Bladder, Overactive
|
| pubmed:year |
2009
|
| pubmed:articleTitle |
Sesquiterpene lactone parthenolide ameliorates bladder inflammation and bladder overactivity in cyclophosphamide induced rat cystitis model by inhibiting nuclear factor-kappaB phosphorylation.
|
| pubmed:affiliation |
Department of Urology, Osaka University Graduate School of Medicine, Suita, Japan.
|
| pubmed:publicationType |
Journal Article,
Comparative Study
|